Delivery Order SPE2DB20D1004-SPE2DB21FF1A2
- Not listed
- This federal contract award, valued at $3,109.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical products...
- This federal contract award, valued at $3,760.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of...
- This federal contract award, valued at $82,418.45, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical...
- This federal contract award, valued at $2,461.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to provide a comprehensive range of...
- This federal contract award, valued at $54,571.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC enables Amerisourcebergen to efficiently deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,103.10, is a delivery order under an Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and AmerisourceBergen, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of...
- This federal contract award, valued at $1,195.55, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $5,429.64, is a delivery order under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, worth up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award, valued at $3,436.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical...
- This federal contract award, valued at $3,739.86, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB21FF1A2Delivery Order
This federal contract award, valued at $3,445.42, was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which runs through December 2025. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 1/22/21 |